Chemical Risk Sciences

Center for Human Health Assessment

Director, Harvey J. Clewell III, Ph.D.

Mission

By combining computational modeling, tissue dosimetry, and cellular response, the Center for Human Health Assessment is forging a new era for human health risk assessments based on perturbation of human biology rather than on uncertain extrapolations from high-dose responses in rodents. These assessments also aid in the development of new pharmaceuticals and offer alternatives to live animal testing.

Health Assessment Experience

  • The Hamner has developed a systems biology approach to provide integrative and quantitative tools for human health effects research.
  • Scientists affiliated with the Center for Human Health Assessment have a long history of seminal research on the effects of chemicals on human health.
  • CIIT and The Hamner have well-established collaborative relationships with area research facilities and government agencies.
  • Risk assessments developed for specific chemicals by The Hamner staff can serve as templates for similar assessments of other compounds.

Current Projects

  • Acetaldehyde and Acrolein Dose-Response Assessments for Humans
  • Biologically Based Risk Assessment for Inhaled Formaldehyde
  • Computational Modeling of Chloroform Cytolethality and Regenerative Proliferation
  • Investigation of Selected Tissues Relevant to Human Health Risk Assessment for Arsenic PBPK Modeling for Risk Assessment of Carbaryl Lawn Post-Application Exposure
  • Reconstructing Human Chloroform Exposure from Biomonitoring Data with a Physiologically Based Pharmacokinetic Model
  • A Reverse Dosimetry Screening Approach for Interpretation of Biomonitoring Data on Volatile Organic Compounds
  • The Role of Regenerative Cellular Proliferation in Propylene Oxide-Induced Rat Nasal Tumors
  • Use of Physiologically-Based Pharmacokinetic Models for Trihalomethanes to Interpret Human Biomonitoring Data Courses

Previously Held Courses

  • Center for Human Health Assessment to Offer Physiologically-Based Pharmacokinetic Modeling and Risk Assessment Workshop was held in February 2008.
  • Physiologically Based Pharmacokinetic (PBPK) Modeling and Risk Assessment was held in September 2005 and again in February 2006.
  • Interpretation of Biomonitoring Data Using Physiologically Based Pharmacokinetic (PBPK) Modeling was held in September 2006.

Future Courses

Physiologically Based Pharmacokinetic (PBPK) Modeling
in Drug Development and Evaluation Workshop

April 6-10, 2009